Climb Bio, Inc. Common Stock (CLYM)
PHARMACEUTICAL PREPARATIONS
Climb Bio, Inc. Common Stock (CLYM) is listed on Nasdaq, where it has traded since August 10, 2021.
- Listed On
- Nasdaq
- Listed Since
- August 10, 2021
- Employees
- 29
- Market Cap
- $585M
About Climb Bio, Inc. Common Stock
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 106 institutions reported holding CLYM, with 56.3 million shares worth $734.4 million in aggregate. The largest reported holder was RA Capital Management, with 11.3 million shares worth $147.4 million. Of the 5 largest holders listed below, 1 opened a new position in CLYM, 3 added shares and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| RA Capital Management | 11,300,939 | $147M | Unchanged |
| FMR | 6,790,364 | $89M | Added 106049.19% |
| UBS Group | 3,404,866 | $44M | Added 3861.68% |
| Braidwell | 2,797,375 | $36M | Added 82.87% |
| Adage Capital Partners GP | 2,506,000 | $33M | New position |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is CLYM?
Climb Bio, Inc. Common Stock (CLYM) is listed on Nasdaq, where it has traded since August 10, 2021.
Who are the largest institutional holders of CLYM?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of CLYM were RA Capital Management, FMR and UBS Group.
How many institutions own CLYM?
106 institutions reported a position in CLYM for the quarter ended June 30, 2026, worth $734.4 million in total.
Did institutions buy or sell CLYM last quarter?
Of the 5 largest reported holders, 1 opened a new position in CLYM, 3 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for CLYM.
Every reported institutional holder, plus insider and congressional trades in CLYM, on SentiSense.